Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

PRAX

Live52w high -3.7%

Annual Quarterly

Core line items from PRAX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: PRAXIS PRECISION MEDICINES, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-326.20M	$-229.15M	$-150.79M	$-74.73M
Net Income	Not available	$-303.27M	$-214.36M	$-71.13M	$-69.30M
EPS (Diluted)	$-3.75	$-13.48	$-9.97	$-6.60	$-3.29
Total Assets	Not available	$937.91M	$396.39M	$452.83M	$478.74M
Total Liabilities	Not available	$59.77M	$52.88M	$48.61M	$39.52M
Cash & Equivalents	Not available	$357.33M	$149.53M	$157.41M	$165.57M
Free Cash Flow OCF − CapEx	Not available	$-249.12M	$-172.80M	$-107.74M	$-53.01M
Shares Outstanding	Not available	25.20M	21.17M	21.04M	20.34M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from PRAX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -3.7%

Entity: PRAXIS PRECISION MEDICINES, INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-08-03	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Operating Income	Not available	$-326.20M	$-229.15M	$-150.79M	$-74.73M
Net Income	Not available	$-303.27M	$-214.36M	$-71.13M	$-69.30M
EPS (Diluted)	$-3.75	$-13.48	$-9.97	$-6.60	$-3.29
Total Assets	Not available	$937.91M	$396.39M	$452.83M	$478.74M
Total Liabilities	Not available	$59.77M	$52.88M	$48.61M	$39.52M
Cash & Equivalents	Not available	$357.33M	$149.53M	$157.41M	$165.57M
Free Cash Flow OCF − CapEx	Not available	$-249.12M	$-172.80M	$-107.74M	$-53.01M
Shares Outstanding	Not available	25.20M	21.17M	21.04M	20.34M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.